Immunology is a complex area of research encompassing diverse patient populations and products that target various aspects of the immune response. CTI has led multi-national development programs that have resulted in dozens of marketing approvals across the spectrum of immunology research, including therapeutics and devices. We understand the challenges associated with drug development in these complex and critically ill patient populations.
Immuno-oncology is the frontier of personalize medicine, and it is an area CTI excels in. Approximately 30% of CTI's most recent programs are in oncology and cell therapy, and over half of our recent projects are deeply rooted in immunological indications. Our approach has stayed true to our therapeutic focus and clinical trial expertise. We focus in complex and critically ill patient populations, bringing a huge reservoir of immunology and cellular therapy expertise to these programs.